Font size
WorksheetsMSK 1
Total questions: 155
Worksheet time: 1hrs 29mins
____ relates the concentration of the drug at the receptor to the magnitude of the response
pharmacokinetics
pharmacodynamics
the _________ leads to the effect we're looking for
drug
drug-receptor complex
receptor
ligand that binds to a receptor and thereby results in a biological response
agonist
partial agonist
antagonist
inverse agonist
ligand that produces less than maximal response
agonist
partial agonist
antagonist
inverse agonist
ligand that diminishes the response of the receptor
agonist
partial agonist
antagonist
inverse agonist
ligand that binds to the same receptor site as the agonist, but reverses the activity of the receptor
agonist
partial agonist
antagonist
inverse agonist
an antagonist
does nothing if there is no basal response
always diminishes the response
will stop the activity if there is basal response
morphine is an example of a(n)
agonist
partial agonist
antagonist
inverse agonist
codeine is an example of a(n)
agonist
partial agonist
antagonist
inverse agonist
naloxone is an example of a(n)
agonist
partial agonist
antagonist
inverse agonist
in the pharmacodynamic sigmoid Emax model, the E is ____
the pharmacologic effect
the maximum pharmacologic effect
the concentration of the ligand at the receptor site
the parameter describing the sigmoid nature of the curve
the plasma concentration required to achieve half of the maximum effect
in the pharmacodynamic sigmoid Emax model, the Emax is ____
the pharmacologic effect
the maximum pharmacologic effect
the concentration of the ligand at the receptor site
the parameter describing the sigmoid nature of the curve
the plasma concentration required to achieve half of the maximum effect
in the pharmacodynamic sigmoid Emax model, the EC50 is ____
the pharmacologic effect
the maximum pharmacologic effect
the concentration of the ligand at the receptor site
the parameter describing the sigmoid nature of the curve
the plasma concentration required to achieve half of the maximum effect
in the pharmacodynamic sigmoid Emax model, the C is ____
the pharmacologic effect
the maximum pharmacologic effect
the concentration of the ligand at the receptor site
the parameter describing the sigmoid nature of the curve
the plasma concentration required to achieve half of the maximum effect
in the pharmacodynamic sigmoid Emax model, the n is ____
the pharmacologic effect
the maximum pharmacologic effect
the concentration of the ligand at the receptor site
the parameter describing the sigmoid nature of the curve
the plasma concentration required to achieve half of the maximum effect
select all that are true
the law of diminishing returns claims that you will observe smaller increments in response as the drug concentration increases
the law of diminishing returns claims that you will observe larger increments in response as the drug concentration decreases
larger values of "n" will demonstrate greater changes in effect at concentrations near EC50
smaller values of "n" will demonstrate greater changes in effect at concentrations near EC50
_____ is an effect, _____ is a concentration
Emax, EC50
EC50, Emax
in PK we look at _____. in PD we look at _____
concentration vs time; pharmacologic response vs concentration
pharmacologic response vs concentration; concentration vs time
this pharmacodynamic response occurs on a scale or continuum
continuous
graded
quantal
dichotomous
this pharmacodynamic response cannot be continuously correlated with drug concentration
continuous
graded
quantal
dichotomous
what are some reasons that it's clinically difficult to determine the "true" Emax
it may not be ethical to reach that effect
metabolites or adverse effects can put a limit on the maximum tolerated concentration
in dichotomous responses we evaluate the response from
drug concentration
cumulative frequency
EC50 refers to a concentration that will produce a predetermined response in 50% of patients
____ measures the activity of a ligand in terms of the concentration required to produce the defined effect
potency
efficacy
____ describes the way by which agonists vary in response, even when occupying the same number of receptors
potency
efficacy
______ is displayed when a lower drug concentration is required to achieve the same response
higher potency
lower potency
greater efficacy
lesser efficacy
______ is displayed when you get a larger response with the same drug concentration as another compound
higher potency
lower potency
greater efficacy
lesser efficacy
what factors affect the relationship between plasma concentration and physiologic response
reversible vs. irreversible effects
direct vs. indirect mechanism of action
plasma and effect site concentration
hysteresis loops (tolerance and sensitization)
in a direct pharmacodynamic link/response
can usually relate plasma concentration to effect
cannot relate plasma concentration to effect
not normally a time delay between administration and resulting effect
there may be a temporal dissociation between change in concentration vs. effect
in an indirect pharmacodynamic link/response
can usually relate plasma concentration to effect
cannot relate plasma concentration to effect
not normally a time delay between administration and resulting effect
there may be a temporal dissociation between change in concentration vs. effect
counter-clockwise hysteresis (the time delay between the measured plasma concentration and the observed effect) is
sensitization
tolerance
tachyphylaxis
clockwise hysteresis (the time delay between the measured plasma concentration and the observed effect) is
sensitization
tolerance
tachyphylaxis
in counter-clockwise hysteresis
response increases at later time points
you can draw two straight lines up and hit the graph twice
increase in response with time at the same effect site concnetration
what are some reasons that sensitization (counter-clockwise hystereisis) can occur
delayed distribution to the site of action
accumulation of active metabolites
upregulation of receptors
an indirect MOA
clockwise hysteresis (proteresis)
effect is decreased at later time points
due to tolerance: a decrease in the pharmacologic response following prolonged exposure to a drug
tachyphylaxis can occur which is an abrupt and complete cessation of effect
what are some reasons tolerance can occur
inactive, competing metabolites
downregulation of receptors
decreased affinity between drug and receptor
decreased response generated from the receptor following drug binding
how do we prevent tachyphylaxis from occuring
we cannot
drug-free intervals are required in order to keep the drug working
we give more of the drug to make sure it keeps working
PK vs. PD drug and disease interactions: enzyme inhibition
PK
PD
PK vs. PD drug and disease interactions: enzyme induction
PK
PD
PK vs. PD drug and disease interactions: changes in metabolism
PK
PD
PK vs. PD drug and disease interactions: changes in organ function
PK
PD
PK vs. PD drug and disease interactions: CNS depressants
PK
PD
PK vs. PD drug and disease interactions: Anticoagulants
PK
PD
PK vs. PD drug and disease interactions: Anticonvulsants
PK
PD
PK vs. PD drug and disease interactions: QT-prolonging agents
PK
PD
PK vs. PD drug and disease interactions: drug concentration changed
PK
PD
t/f: dosage form/route of administration does not have a significant effect on onset and duration of analgesia
true
false
t/f: changes in dosing regimens are driven primarily by efficacy and tolerability
true
false
t/f: onset and duration of analgesia will be a result of combined PK, MOA, receptor location, dosage form, and patient factors
true
false
t/f: PD is sometimes related to the side effects of a class of drugs where the side effects become the targeted pharmacologic outcome
true
false
n-acetyl-cysteine
acts as a glutathione substitute and binds the NAPQI metabolite
ideally want to start this within 8-10 hours of OD, but patients are relatively asymptomatic for 24-36 hours
it will not undo the damage already done
which is expressed in response to insult/injury
COX-1
COX-2
t/f: must functions, including GI protection, renal function, and inflammation are impacted by at least two prostaglandins
true
false
there is no ____ in platelets
COX-1
COX-2
COX-2 selective drugs were developed in order to
inhibit some of the COX-1 side effects
COX-2 is more upregulated and released in response to injury, it will not affect housekeeping
because platelets do not have a nucleus, they cannot inhibit platelet aggregation. when you inhibit with COX-2...
you lose your protection against platelet aggregation, leading to the sticky platelet phenomenon
also leads to increased CV risk
there is now an imbalance of prothrombic state and antithrombic state
this is called the mechanism-based Fitzgerald hypothesis
what are you at risk for if children use ASA
reye's syndrome
SJS
what patients should not use ASA
a 7 year old with community-acquired pneumonia
a 60 year old woman with heart failure
a 18 year old male with asthma
a 40 year old woman with nasal polyps
a 21 year old with rhinitis
t/f: gralise and horizant are interchangeable with other gabapentin products
true
false
which chemical mediator increases vascular permeability, and increases blood flow to the injured area
histamine
prostaglandins and leukotrienes
phagocytes
serotonin
which chemical mediator(s) is (are) involved in pain response, vascular permeability, and chemotaxis
histamine
prostaglandins and leukotrienes
phagocytes
serotonin
which chemical mediator(s) increase capillary blood flow and vascular permeability
histamine
prostaglandins and leukotrienes
phagocytes
serotonin
prostaglandins have (a) carbons
what is the only NSAID that irreversibly covalently modifies COX by acetylating Ser530 of COX-1 and SER516 of COX-2.
ASA
ibuprofen
diclofenac
sulindac
salicylates are more potent against ___ than ___ which is why we see so many side effects with ASA
COX-1, COX-2
COX-2, COX-1
ASA should be avoided in patients with
hypoprothrombinemia
vitamin k deficiency
history of peptic ulcer or GI bleeds
ASA hypersensitivity
as effective as ASA but few side effects. does not cause GI bleeds and can be given to ASA sensitive patients
salsalate
salicylamide
diflunisal
has an amide group instead of a carboxylic acid. it is not acidic which means there's a lack of gastric irritation. this one can be used in patients with ASA hypersensitivity. has minimal anti-inflammatory activity
salsalate
salicylamide
diflunisal
longer-acting, slower onset. more potent and more effective than ASA but fewer side effects. this one is also much more expensive
salsalate
salicylamide
diflunisal
one of the most potent NSAIDS in use. more potent than ASA and acetaminophen (10x analgesic potency of ASA)
indomethacin
sulindac
ketorolac
naproxen
nabumetone
has way too many side effects to be used long term
indomethacin
sulindac
ketorolac
naproxen
nabumetone
a non-nitrogenous analog of indomethacin
fenoprofen
sulindac
ketorolac
naproxen
nabumetone
can be used long-term because there are limited side effects
indomethacin
sulindac
ketorolac
naproxen
nabumetone
there is a sulfoxide group on the compound. when it is reduced to sulfide, we get the active form of the drug. when it's oxidized to sulfone, we get the inactive form
indomethacin
sulindac
ketorolac
naproxen
nabumetone
if the R group is a hydrogen it's _____. if the R group is a methyl it's _____.
ibuprofen, ibuprofenac
ibuprofenac, ibuprofen
in most racemic arylacetic acid derivatives, the ____ is the only isomer with anti-inflammatory activity
S(+)
S(-)
R(+)
R(-)
in terms of potency, put these in order from most potent to least: ibuprofen, indomethacin, ASA
(a)
in this med, caution use with hydantoins, sulfonamides, and sulfonylureas. this drug displaces the drugs listed from their binding sites and can cause toxicity
fenoprofen
ibuprofen
tolmetin
naproxen
an arylacetic acid derivative that is NOT sold as a racemic mixture. Only the S(+) isomer is obtained and marketed
ibuprofen
naproxen
fenoprofen
indomethacin
not recommended for pregnant or lactating women
ibuprofen
naproxen
ketoprofen
suprofen
not recommended for children under 16
ibuprofen
naproxen
ketoprofen
suprofen
has more anti-inflammatory activity than phenylbutazone but less than indomethacin. it's COX-2 selective analog was removed from the market due to anaphylaxis, particularly in patients with ASA sensitivity
tolmetin
ketoprofen
suprofen
nabumetone
instead of inhibiting COX, this drug inhibits the synthesis of leukotrienes and leukocyte migration into inflamed joints in addition to inhibiting the biosynthesis of prostaglandins
ketoprofen
tolmetin
suprofen
nabumetone
mainly used as 1% ophthalmic solution for prevention of surgically induced miosis during cataract extraction
ketoprofen
tolmetin
suprofen
nabumetone
oral dosage forms have been discontinued due to renal effects
ketoprofen
tolmetin
suprofen
nabumetone
this is NOT an arylacetic acid. it is a ketone. it is non-acidic which decreases GI side effects. the active metabolite IS an acetic acid.
nabumetone
oxaprozin
flurbiprofen
ketorolac
a propionic acid derivative with an a-methyl group
nabumetone
oxaprozin
flurbiprofen
ketorolac
1st topical NSAID indicated for ophthalmic use in the US
nabumetone
diclofenac
flurbiprofen
ketorolac
inhibits intraoperative miosis induced by prostaglandins in cataract surgery
oxaprozin
diclofenac
flurbiprofen
ketorolac
a cyclized heteroaryl propionic acid derivative with a-methyl group fused to the pyrrole ring. this is done for rigidity.
oxaprozin
diclofenac
flurbiprofen
ketorolac
relatively more effective as an analgesic than as an anti-inflammatory
oxaprozin
etodolac
flurbiprofen
ketorolac
relief of ocular itching caused by seasonal allergies
suprofen
etodolac
flurbiprofen
ketorolac
contraindicated in patients receiving ASA or NSAIDs due to cumulative risk of inducing serious side effects
suprofen
etodolac
flurbiprofen
ketorolac
diclofenac
belongs to arylacetic acid derivatives, but is also considered a homolog of n-arylanthranillic acid
suprofen
etodolac
flurbiprofen
ketorolac
diclofenac
it inhibits COX but also inhibits the lipooxygenase pathway, resulting production of leukotrienes. it also inhibits arachidonic acid release and stimulation of it's uptake, resulting in a reduction of arachidonic acid availability.
suprofen
etodolac
flurbiprofen
ketorolac
diclofenac
highly selective for COX-2. has a high safety profile.
suprofen
etodolac
flurbiprofen
ketorolac
diclofenac
not strictly an arylacetic acid derivative
suprofen
etodolac
flurbiprofen
ketorolac
oxaprozin
cannot be used safely for more than 7 days
suprofen
etodolac
meclofenamate sodium
mefenamic acid
oxaprozin
can treat primary dysmenorrhea
suprofen
etodolac
meclofenamate sodium
mefenamic acid
oxaprozin
can use for chronic treatment. does have a high incidence of severe diarrhea
suprofen
etodolac
meclofenamate sodium
mefenamic acid
oxaprozin
do not have a COOH but instead have an enolic acid
suprofen
piroxicam
meclofenamate sodium
mefenamic acid
meloxicam
which oxicam is considered a selective COX-2 inhibitor
meloxicam
piroxicam
first marketed selective COX-2 inhibitor
etodolac
piroxicam
celecoxib
meloxicam
side effects include increased risk of serious CV thrombotic events, MI, and stroke
etodolac
piroxicam
celecoxib
meloxicam
proteins in the blood that cause inflammation and affect blood pressure. they also increase blood flow throughout the body, make it easier for fluids to pass through small blood vessels, stimulate pain receptors, and are part of a complex system that helps repair damaged tissues in the body
(a)
catalyzes the intracellular release of arachidonic acid from the phospholipids
(a)
the conversion of arachidonic acid to PGG2 via COX-1 and COX-2 is the ____ ________ ____
(a)
29 year old man drinking 3 shots of whiskey daily
APAP
ibuprofen
either
neither
what percentage of acetaminophen gets metabolized to NAPQI
(a)
what is the specific isoenzyme that makes more NAPQI.
(a)
64 year old taking warfarin for blood clot
APAP
naproxen
either
neither
MM is on warfarin. disregarding all other factors, what could you select for your patient
APAP
NSAIDs
Selective COX-2
Non-acetylated salicylates
CK is on heparin. disregarding all other factors, what could you select for your patient
APAP
NSAIDs
Selective COX-2
Non-acetylated salicylates
JT is on antiplatelets. disregarding all other factors, what could you select for your patient
APAP
NSAIDs
Selective COX-2
Non-acetylated salicylates
PH is on NOACs/DOACs. disregarding all other factors, what could you select for your patient
APAP
NSAIDs
Selective COX-2
Non-acetylated salicylates
NS is on ASA. disregarding all other factors, what could you select for your patient
APAP
NSAIDs
Selective COX-2
Non-acetylated salicylates
76 year old taking gabapentin
APAP
naproxen
either
neither
58 year old with heart failure
APAP
naproxen
either
neither
54 year old with history of GI bleeds
APAP
naproxen
either
neither
50 year old taking 40mg lisinopril daily
APAP
naproxen
neither
either
26 year old woman in her third trimester of pregancy
APAP
ibuprofen
salicylates
naproxen
26 year old woman in her third trimester of pregancy
APAP
ibuprofen
salicylates
naproxen
at (a) weeks gestation it is best to begin avoiding NSAIDs for the remainder of the pregnancy due to the potential to cause fetal kidney dysfunction.
46 year old woman receiving chemotherapy for metastatic breast cancer
APAP
naproxen
APAP or meloxicam
neither
what is safe to use in patients with thrombocytopenia
nonacetylated salicylates
celecoxib
meloxicam
acetaminophen
opioids
34 year old man with aspirin-sensitive asthma
APAP
naproxen
either
neither
72 year old woman taking aspirin and sertraline
APAP
ibuprofen
either
neither
t/f: bleeding can occur with low-dose ASA alone
true
false
44 year old s/p roux-en y gastric bypass
acetaminophen
naproxen
either
neither
32 year old woman taking 20mg prednisone daily
acetaminophen
naproxen
either
neither
32 year old woman taking 20mg prednisone daily
acetaminophen
naproxen
either
neither
found in the skin, subcutaneous tissue, and mucous membranes
superficial somatic pain
deep somatic pain
visceral pain
due to external mechanical, chemical, or thermal events
superficial somatic pain
deep somatic pain
visceral pain
found in muscles, tendons, joints, and bones.
superficial somatic pain
deep somatic pain
visceral pain
due to overuse, strain, mechanical injury, cramping, or inflammation
superficial somatic pain
deep somatic pain
visceral pain
carries proprioceptive signals, it is myelinated, the largest, and has the quickest conduction speed
a-alpha
a-beta
a-delta
c
carries touch signals. it is myelinated, the second largest, and has the second quickest conduction speed
a-alpha
a-beta
a-delta
c
not involved in pain signals unless there is a change in the nervous system. this is called allodynia.
a-alpha
a-beta
a-delta
c
carries pain signals. it is myelinated. it carries the faster, more sharp-feeling pain. it has mechanoreceptors
a-alpha
a-beta
a-delta
c
carries pain signals. it is not myelinated. it carries the slower pain which manifests as burning, aching, and gnawing. it is responsive to changes in temperature
a-alpha
a-beta
a-delta
c
carries pain signals. it is not myelinated. it carries the slower pain which manifests as burning, aching, and gnawing. it is responsive to changes in temperature. it is chemically activated
a-alpha
a-beta
a-delta
c
peripheral stimulus to dorsal root ganglion
transduction
conduction
transmission
perception
modulation
action potential from dorsal root ganglion to dorsal horn of the spinal cord
transduction
conduction
transmission
perception
modulation
dorsal horn of the spinal cord
transduction
conduction
transmission
perception
modulation
thalamus to reach somatic/sensory cortex and premotor cortex
transduction
conduction
transmission
perception
modulation
brainstem to spinal cord
transduction
conduction
transmission
perception
modulation
transduction
chemical
electrical
conduction
chemical
electrical
perception
chemical
electrical
chemical to electrical
transduction
conduction
transmission
perception
modulation
chemical and electrical
transduction
conduction
perception
modulation
incredibly complex GCPRs that are cell surface bound and set off a cascade of secondary messenger systems once a drug is bound that reduce the depolarization that is occuring
opioid receptors
voltage gated calcium channels
presynaptic channels on the peripheral nociceptor
opioid receptors
voltage gated calcium channels
there are two endogenous purine synthesis genetic enzyme abnormalities. which one is superactivity
PRPP
HGPRT
there are two endogenous purine synthesis genetic enzyme abnormalities. which one is deficiency
PRPP
HGPRT
accumulation of crystalline deposits in soft tissue and bone are called
(a)
